Literature DB >> 20936651

Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells.

Martin B Oleksiewicz1, Christine Bonnesen, Anne Charlotte Hegelund, Anders Lundby, Gitte-Mai Nelander Holm, Marianne B Jensen, Jonas S Krabbe.   

Abstract

We compared mitogenicity and intracellular signalling by human insulin and the AspB10 (X-10) human insulin analogue in MCF-7 human mammary adenocarcinoma cells. By flow analysis of phosphorylated histone H3 or cell cycle distributions, insulin and X-10 were mitogenic at physiologically relevant concentrations (2 nm to 74 pm range), with X-10 being approximately 3-fold more mitogenic than insulin. By western blotting with phospho-specific antibodies, insulin induced phosphorylation of IRS-1, Akt, p70S6K, S6 ribosomal protein, 4E-BP1, FoxO3a, FoxO1, p44/42 MAPK and the EGFR. Blocking with wortmannin, rapamycin and U0126 showed that these signalling events conformed to the canonical PI3K pathway. IRS-1 (Ser302) phosphorylation was abolished by wortmannin and rapamycin, suggesting a feedback from the PI3K pathway on insulin signalling. Compared with equimolar insulin, X-10 caused up to 2-fold higher phosphorylation of all proteins examined in this study. The phosphorylation sites that responded most strongly to insulin were not generally the same as those responding most strongly to X-10. In the PI3K pathway, the most X-10-sensitive protein localized to the translation-regulating arm (p70S6K), with FoxO3a and FoxO1 transcription factors showing a more comparable response to insulin and X-10. Using flow analysis, we confirmed the correlation between insulin-triggered translational activation in G0/G1 (S6 phosphorylation) and S-phase entry by MCF-7 cells. In summary, our findings implicate asymmetrical PI3K pathway activation and specifically stimulation of protein translation in the hypermitogenic effect of insulin analogues such as X-10. It remains to be shown whether these findings are relevant to other human mammary cancer cell types.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936651     DOI: 10.1002/jat.1590

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  8 in total

Review 1.  Insulin X10 revisited: a super-mitogenic insulin analogue.

Authors:  B F Hansen; P Kurtzhals; A B Jensen; A Dejgaard; D Russell-Jones
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.

Authors:  Emily Jane Gallagher; Nyosha Alikhani; Aviva Tobin-Hess; Jeffrey Blank; Nicholas J Buffin; Zara Zelenko; Norbert Tennagels; Ulrich Werner; Derek LeRoith
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

Review 3.  Ligand bias in receptor tyrosine kinase signaling.

Authors:  Kelly Karl; Michael D Paul; Elena B Pasquale; Kalina Hristova
Journal:  J Biol Chem       Date:  2020-10-29       Impact factor: 5.157

Review 4.  The metabolic and mitogenic properties of basal insulin analogues.

Authors:  Norbert Tennagels; Ulrich Werner
Journal:  Arch Physiol Biochem       Date:  2013-02       Impact factor: 4.076

5.  Agonism and antagonism at the insulin receptor.

Authors:  Louise Knudsen; Bo Falck Hansen; Pia Jensen; Thomas Åskov Pedersen; Kirsten Vestergaard; Lauge Schäffer; Blagoy Blagoev; Martin B Oleksiewicz; Vladislav V Kiselyov; Pierre De Meyts
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

6.  Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.

Authors:  Heleen K Bronsveld; Bas ter Braak; Øystein Karlstad; Peter Vestergaard; Jakob Starup-Linde; Marloes T Bazelier; Marie L De Bruin; Anthonius de Boer; Christine L E Siezen; Bob van de Water; Jan Willem van der Laan; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

Review 7.  Role of insulin in the type 2 diabetes therapy: past, present and future.

Authors:  Carlo Maria Rotella; Laura Pala; Edoardo Mannucci
Journal:  Int J Endocrinol Metab       Date:  2013-07-01

8.  Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts.

Authors:  Henning Hvid; Marie-José Blouin; Elena Birman; Jesper Damgaard; Fritz Poulsen; Johannes Josef Fels; Christian Fledelius; Bo Falck Hansen; Michael Pollak
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.